HomeAI · summaries
Storia in 8 fonti
Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO chief
As health officials grapple with a fast-moving outbreak of the Bundibugyo ebolavirus in the Democratic Republic | Officials are planning to study Mapp Biopharmaceutical’s MBP134 and Gilead Sciences’ remdesivir, which gained prominence during the COVID-19 pandemic, against the Bundibugyo ebolavirus.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
thecitizen.co.tz
US provides Ebola treatment for outbreak in Congo, bringing trials closer
Phase 1 trials could begin in July, likely in the UK and possibly Uganda, Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations, said in an…
- ·
dailysabah.com
US sends experimental Ebola drug to DRC as outbreak trials expand
The United States is stepping into a more direct role in the Ebola response in the Democratic Republic of Congo by supplying doses of an experimental...
